Company Overview
About ConcertAI
ConcertAI is a Boston-based company that combines artificial intelligence with real-world oncology data to accelerate cancer drug development and improve patient outcomes. Its platform integrates multi-modal patient data — including electronic health records, genomics, imaging, and pathology — from a network of oncology providers to support biopharma companies in clinical trial design, site selection, protocol optimization, patient matching, and regulatory submission.
Business Model & Competitive Advantage
The company acquired CancerLinQ from the American Society of Clinical Oncology (ASCO) in December 2023, expanding its real-world data (RWD) assets to 5.5 million multi-modal oncology patient records — the largest curated oncology RWD repository in the US. ConcertAI has raised over $230 million including a $150 million Series C in March 2022 at a $1.9 billion valuation, with investors including SoftBank Vision Fund 2. The company exited FY2024 profitable, reporting mid-teens unadjusted EBITDA margins and the highest annual recurring revenue (ARR) ratio in company history at 72%.
Competitive Landscape 2025–2026
ConcertAI's CARAai platform powers its data-as-a-service (DaaS) and AI SaaS offerings, with an expanding collaboration with NVIDIA in medical imaging announced for 2025. The company serves 40+ biopharma clients and regulatory bodies, positioning itself as the connective intelligence layer between oncology real-world evidence and the clinical and regulatory decisions that bring cancer treatments to patients.
Key Differentiators
Market Leader
ConcertAI is recognized as a market leader in the Life Sciences & BioTech sector, demonstrating strong industry presence and customer trust.
Frequently Asked Questions
Similar Brands
Illumina
Illumina was founded in 1998 in San Diego and has grown into the undisputed leader in next-generation sequencing (NGS), with approximately 80% global market share across research and clinical applicat
BioNTech
BioNTech SE was founded in 2008 in Mainz, Germany by Ugur Sahin, Ozlem Tureci, and Christoph Huber with a mission to harness the immune system for individualized cancer treatment. The company pioneere
Neuralink
Neuralink is a neurotechnology company founded in 2016 by Elon Musk and a team of neuroscientists and engineers, developing implantable brain-computer interface devices that enable individuals with pa
Genentech
Genentech was founded in 1976 in South San Francisco by Herbert Boyer and Robert Swanson, becoming the first company to produce human insulin using recombinant DNA technology and essentially launching
Regeneron
Regeneron Pharmaceuticals was founded in 1988 in Tarrytown, New York by Leonard Schleifer and George Yancopoulos. The company built its reputation on the Velocimmune platform—a proprietary humanized m
Cradle
Cradle is a protein design platform using AI to help biotechnology and pharmaceutical companies engineer better proteins — enzymes, antibodies, and therapeutic proteins — with improved stability, acti
Compare ConcertAI with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from ConcertAI? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim ConcertAI Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention ConcertAI vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →